TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN CARDIAC AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN CARDIAC AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for heart transplant patients: drug may stop amyloidosis spread
Disease control Recruiting nowThis study tests whether the drug tafamidis can safely stop the progression of ATTR amyloidosis in other organs after a heart transplant. About 25 adults who had a heart transplant at least a year ago will take tafamidis for 12 months. Researchers will measure protein stability i…
Matched conditions: TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
AI heart scanner could spot rare disease before It's too late
Diagnosis Recruiting nowThis study checks if an artificial intelligence (AI) system called Willem can spot a rare heart condition called transthyretin cardiac amyloidosis (ATTR-CA) by analyzing standard ECG recordings. Researchers will look at past ECGs from 2,000 adults (18 and older) to see how well t…
Matched conditions: TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Sponsor: Idoven 1903 S.L. • Aim: Diagnosis
Last updated May 26, 2026 11:53 UTC